Checkpoint inhibitors in mesothelioma:: Hope for the future?

Anna Bibby; Nick Maskell

doi:10.1016/S1470-2045(18)30868-4

Checkpoint inhibitors in mesothelioma: Hope for the future?

Anna Bibby, Nick Maskell

Research output: Contribution to journal › Article (Academic Journal) › peer-review

4 Citations (Scopus)

267 Downloads (Pure)

Abstract

[no abstract]

Original language	English
Pages (from-to)	172-174
Number of pages	3
Journal	Lancet Oncology
Volume	20
Issue number	2
Early online date	16 Jan 2019
DOIs	https://doi.org/10.1016/S1470-2045(18)30868-4
Publication status	Published - 1 Feb 2019

Research Groups and Themes

Academic Respiratory Unit

Access to Document

10.1016/S1470-2045(18)30868-4

Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30868-4/fulltext#seccestitle10. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 173 KB

Handle.net

Persistent link

Cite this

@article{27c4b8dfaedd411bb5d68c9a44f278d0,

title = "Checkpoint inhibitors in mesothelioma:: Hope for the future?",

abstract = "[no abstract]",

author = "Anna Bibby and Nick Maskell",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/S1470-2045(18)30868-4",

language = "English",

volume = "20",

pages = "172--174",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Checkpoint inhibitors in mesothelioma:

T2 - Hope for the future?

AU - Bibby, Anna

AU - Maskell, Nick

PY - 2019/2/1

Y1 - 2019/2/1

N2 - [no abstract]

AB - [no abstract]

UR - http://www.scopus.com/inward/record.url?scp=85060880947&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30868-4

DO - 10.1016/S1470-2045(18)30868-4

M3 - Article (Academic Journal)

C2 - 30660608

AN - SCOPUS:85060880947

SN - 1470-2045

VL - 20

SP - 172

EP - 174

JO - Lancet Oncology

JF - Lancet Oncology

IS - 2

ER -